

# Contents

|                     |       |
|---------------------|-------|
| <b>Contributors</b> | xix   |
| <b>Preface</b>      | xxiii |
| <b>Glossary</b>     | xxvii |

|                                      |          |
|--------------------------------------|----------|
| <b>PART I ENZYMES AND METABOLISM</b> | <b>1</b> |
|--------------------------------------|----------|

|                                  |          |
|----------------------------------|----------|
| <b>1 Glutamate Dehydrogenase</b> | <b>3</b> |
|----------------------------------|----------|

*T.J. Smith and C.A. Stanley*

|                                                                |    |
|----------------------------------------------------------------|----|
| 1.1 Abstract                                                   | 3  |
| 1.2 Introduction                                               | 3  |
| 1.3 GDH in Animals                                             | 3  |
| 1.3.1 Structure of animal GDH                                  | 4  |
| 1.4 Active Site                                                | 5  |
| 1.4.1 GDH dynamics                                             | 7  |
| 1.4.2 GTP inhibition site                                      | 7  |
| 1.4.3 ADP/second NADH site paradox                             | 8  |
| 1.5 Role of GDH in Insulin Homeostasis                         | 11 |
| 1.5.1 HHS                                                      | 11 |
| 1.5.2 SIRT4 mutations                                          | 13 |
| 1.5.3 SCHAD mutations                                          | 13 |
| 1.6 Evolution of GDH Allostery                                 | 14 |
| 1.6.1 Possible therapeutics for GDH-mediated insulin disorders | 16 |
| 1.6.2 Other novel inhibitors of GDH                            | 17 |
| 1.7 Conclusions                                                | 19 |
| 1.8 Acknowledgements                                           | 19 |

|                            |           |
|----------------------------|-----------|
| <b>2 Aminotransferases</b> | <b>24</b> |
|----------------------------|-----------|

*M.E. Conway*

|                  |    |
|------------------|----|
| 2.1 Abstract     | 24 |
| 2.2 Introduction | 24 |

|          |                                                                                                     |           |
|----------|-----------------------------------------------------------------------------------------------------|-----------|
| 2.2.1    | Transamination                                                                                      | 25        |
| 2.2.2    | Cellular distribution of aminotransferases                                                          | 25        |
| 2.2.2.1  | Cellular distribution of the BCAT proteins                                                          | 27        |
| 2.2.2.2  | Cellular distribution of the ALT proteins                                                           | 27        |
| 2.2.2.3  | Cellular distribution of the AST proteins                                                           | 28        |
| 2.3      | The Role of Aminotransferases in Brain Metabolism                                                   | 28        |
| 2.3.1    | The role of BCAT in brain metabolism                                                                | 31        |
| 2.4      | Alanine Aminotransferases and Glutamate                                                             | 34        |
| 2.5      | Aspartate Aminotransferases and their Role in the Malate–Aspartate Shuttle and Glutamate Metabolism | 35        |
| 2.6      | Pathological Conditions Resulting from Impaired Aminotransferase Metabolism                         | 36        |
| 2.6.1    | Maple syrup urine disease                                                                           | 37        |
| 2.6.2    | Glutamate toxicity and neurodegeneration                                                            | 37        |
| 2.6.3    | Redox sensitivity of BCAT                                                                           | 38        |
| 2.7      | Aminotransferase Proteins as Biomarkers of Disease                                                  | 38        |
| 2.7.1    | Mild elevation of ALT and AST                                                                       | 39        |
| 2.7.2    | Moderate/marked elevation of ALT and AST                                                            | 41        |
| 2.8      | Conclusions and Future Directions                                                                   | 41        |
| <b>3</b> | <b>Arginase</b>                                                                                     | <b>51</b> |
|          | <i>R.W. Caldwell, S. Chandra and R.B. Caldwell</i>                                                  |           |
| 3.1      | Abstract                                                                                            | 51        |
| 3.2      | Introduction                                                                                        | 51        |
| 3.3      | Isoforms and Distribution                                                                           | 53        |
| 3.4      | Structure and Location of Arginase                                                                  | 53        |
| 3.5      | Involvement of Arginase in Health and Disease                                                       | 54        |
| 3.5.1    | Arginase in health                                                                                  | 54        |
| 3.5.1.1  | Ammonia detoxification                                                                              | 54        |
| 3.5.1.2  | Wound healing                                                                                       | 54        |
| 3.5.1.3  | Neuroprotection/regeneration                                                                        | 55        |
| 3.5.2    | Arginase in disease                                                                                 | 55        |
| 3.5.2.1  | Diabetes                                                                                            | 55        |
| 3.5.2.2  | Hypertension                                                                                        | 55        |
| 3.5.2.3  | Sickle cell disease                                                                                 | 56        |
| 3.5.2.4  | Erectile dysfunction                                                                                | 56        |
| 3.5.2.5  | Asthma                                                                                              | 57        |
| 3.5.2.6  | Ischaemia/reperfusion injury                                                                        | 57        |
| 3.5.2.7  | Atherosclerosis                                                                                     | 57        |
| 3.5.2.8  | Nephropathy                                                                                         | 58        |
| 3.5.2.9  | Cancer                                                                                              | 58        |
| 3.5.2.10 | Parasitic infection                                                                                 | 59        |
| 3.5.2.11 | Hyperargininaemia                                                                                   | 59        |
| 3.5.2.12 | Ageing                                                                                              | 59        |
| 3.5.2.13 | Retinopathy                                                                                         | 60        |
| 3.6      | Regulation of Activity                                                                              | 60        |
| 3.6.1    | Humoral factors                                                                                     | 60        |
| 3.6.1.1  | Reactive oxygen species                                                                             | 60        |
| 3.6.1.2  | Angiotensin II                                                                                      | 61        |
| 3.6.2    | Elevation of arginase activity and signal transduction mechanisms                                   | 61        |
| 3.7      | Arginase Inhibitors                                                                                 | 62        |
| 3.8      | Conclusions                                                                                         | 63        |

|          |                                                                                                                                         |            |
|----------|-----------------------------------------------------------------------------------------------------------------------------------------|------------|
| <b>4</b> | <b>Bypassing the Endothelial L-Arginine–Nitric Oxide Pathway:<br/>Effects of Dietary Nitrite and Nitrate on Cardiovascular Function</b> | <b>72</b>  |
|          | <i>P. Luedike, M. Kelm and T. Rassaf</i>                                                                                                |            |
| 4.1      | Abstract                                                                                                                                | 72         |
| 4.2      | Introduction                                                                                                                            | 72         |
| 4.3      | L-Arginine: A Semi-Essential Amino Acid in Human Physiology                                                                             | 73         |
| 4.4      | L-Arginine is the Substrate of the Nitric Oxide Synthases:<br>The L-Arginine–Nitric Oxide Pathway                                       | 73         |
| 4.5      | L-Arginine in Cardiovascular Disease: Perspectives and Limitations                                                                      | 77         |
| 4.6      | Nitric Oxide Generation without NO-Synthase?<br>Bypassing the L-Arginine Pathway                                                        | 78         |
| 4.7      | The Nitrate–Nitrite–Nitric Oxide Pathway                                                                                                | 79         |
| 4.8      | Effects of Nitrite and Nitrate in Human Physiology                                                                                      | 80         |
| 4.9      | Dietary Nitrate and Nitrite                                                                                                             | 82         |
| 4.10     | Conclusions                                                                                                                             | 83         |
| 4.11     | Acknowledgements                                                                                                                        | 84         |
| <b>5</b> | <b>Histidine Decarboxylase</b>                                                                                                          | <b>89</b>  |
|          | <i>E. Dere, O. Ambrée and A. Zlomuzica</i>                                                                                              |            |
| 5.1      | Abstract                                                                                                                                | 89         |
| 5.2      | Introduction                                                                                                                            | 89         |
| 5.3      | Histidine Decarboxylase Enzyme                                                                                                          | 91         |
| 5.4      | Histidine Decarboxylase Gene                                                                                                            | 91         |
| 5.4.1    | Gene polymorphism                                                                                                                       | 92         |
| 5.5      | Pharmacological Inhibition                                                                                                              | 92         |
| 5.6      | mRNA Antisense and Gene Knockout                                                                                                        | 92         |
| 5.7      | Neurophysiology and Behaviour                                                                                                           | 93         |
| 5.7.1    | Brain neurotransmitters                                                                                                                 | 93         |
| 5.7.2    | Nutrition                                                                                                                               | 93         |
| 5.7.3    | Sleep, waking and arousal                                                                                                               | 94         |
| 5.7.4    | Reward and drugs                                                                                                                        | 94         |
| 5.7.5    | Stress, fear and anxiety                                                                                                                | 95         |
| 5.7.6    | Learning and memory                                                                                                                     | 96         |
| 5.7.6.1  | Dementia                                                                                                                                | 97         |
| 5.8      | Summary and Conclusions                                                                                                                 | 97         |
| 5.9      | Acknowledgements                                                                                                                        | 98         |
| <b>6</b> | <b>Glutamate Decarboxylase</b>                                                                                                          | <b>103</b> |
|          | <i>H. Ueno, Y. Inoue, S. Matsukawa and Y. Nakamura</i>                                                                                  |            |
| 6.1      | Abstract                                                                                                                                | 103        |
| 6.2      | Introduction                                                                                                                            | 103        |
| 6.3      | Distribution of GABA                                                                                                                    | 103        |
| 6.3.1    | GABA storage, release and uptake                                                                                                        | 104        |
| 6.3.2    | GABA receptors                                                                                                                          | 104        |
| 6.3.3    | Metabolism of GABA                                                                                                                      | 105        |
| 6.3.4    | Decarboxylation reaction by GAD                                                                                                         | 105        |
| 6.3.5    | Distribution and characterization of GAD                                                                                                | 107        |
| 6.3.6    | Purification of GAD protein                                                                                                             | 110        |
| 6.3.7    | Gene structure of GAD                                                                                                                   | 110        |
| 6.4      | GAD 65 in Blood Leucocytes                                                                                                              | 110        |

|                                                                 |            |
|-----------------------------------------------------------------|------------|
| 6.5 Taste Signalling                                            | 113        |
| 6.6 Suggestions for Future Research                             | 115        |
| 6.7 Conclusions                                                 | 116        |
| 6.8 Acknowledgements                                            | 117        |
| <b>7 Glutaminase</b>                                            | <b>122</b> |
| <i>J.M. Matés, J.A. Segura, F.J. Alonso and J. Márquez</i>      |            |
| 7.1 Abstract                                                    | 122        |
| 7.2 Introduction                                                | 122        |
| 7.3 Mammalian Glutaminase Genes and Transcripts                 | 123        |
| 7.3.1 <i>Gls</i> gene and transcripts                           | 123        |
| 7.3.2 <i>Gls2</i> gene and transcripts                          | 124        |
| 7.4 Mammalian Glutaminase Enzymes                               | 125        |
| 7.4.1 Molecular structures and kinetic properties               | 126        |
| 7.4.2 Subcellular locations                                     | 127        |
| 7.5 Glutaminase Expression in Mammalian Brain                   | 127        |
| 7.5.1 Expression of glutaminase L in astrocytes                 | 129        |
| 7.6 State of Art and Perspectives                               | 130        |
| 7.7 Conclusions                                                 | 131        |
| 7.8 Acknowledgements                                            | 132        |
| <b>8 D-Serine and Serine Racemase in the Retina</b>             | <b>137</b> |
| <i>S.B. Smith, Y. Ha and V. Ganapathy</i>                       |            |
| 8.1 Abstract                                                    | 137        |
| 8.2 Introduction                                                | 137        |
| 8.3 NMDA Receptor and D-serine as a Co-agonist                  | 139        |
| 8.4 D-Serine in the Retina                                      | 139        |
| 8.5 Mechanisms of D-Serine Uptake in the Retina                 | 140        |
| 8.6 D-Serine and Serine Racemase in Retinal Neurons             | 142        |
| 8.7 Role of D-Serine in the Retina                              | 144        |
| 8.8 Role of D-Serine and Serine Racemase in Neuronal Cell Death | 146        |
| 8.9 Conclusions                                                 | 147        |
| 8.10 Acknowledgements                                           | 148        |
| <b>9 Tryptophan Hydroxylase</b>                                 | <b>150</b> |
| <i>I. Winge, J. McKinney and J. Haavik</i>                      |            |
| 9.1 Abstract                                                    | 150        |
| 9.2 Introduction                                                | 150        |
| 9.3 General Properties                                          | 150        |
| 9.4 Structure and Function of TPH                               | 152        |
| 9.4.1 Domain organization                                       | 152        |
| 9.4.2 Ligand binding                                            | 154        |
| 9.4.3 Catalytic mechanism                                       | 155        |
| 9.5 Enzyme Regulation                                           | 156        |
| 9.5.1 Inhibition of TPH                                         | 156        |
| 9.5.2 Regulation of TPH                                         | 158        |
| 9.5.3 Phosphorylation of TPH                                    | 159        |
| 9.5.4 14-3-3 binding to TPH                                     | 160        |
| 9.6 TPH Knockout Studies                                        | 161        |
| 9.7 Implications of TPH Dysfunction in Human Health             | 161        |
| 9.8 Concluding Remarks and Future Research                      | 164        |

|                                                                                                                                          |            |
|------------------------------------------------------------------------------------------------------------------------------------------|------------|
| <b>10 Methionine Metabolism</b>                                                                                                          | <b>173</b> |
| <i>J.M. Mato, M.L. Martínez-Chantar and S.C. Lu</i>                                                                                      |            |
| 10.1 Abstract                                                                                                                            | 173        |
| 10.2 Introduction                                                                                                                        | 173        |
| 10.3 Proliferating Hepatocytes and Liver Cancer Cells Show a Less Efficient Methionine Metabolism than Normal Differentiated Hepatocytes | 174        |
| 10.4 How Does a Less Efficient Methionine Metabolism Facilitate Hepatocyte Proliferation?                                                | 178        |
| 10.5 Regulation of Methionine Metabolism is a Crucial Step in Liver Regeneration                                                         | 180        |
| 10.6 How do Both a Defect and an Excess of Liver SAMe Trigger HCC?                                                                       | 182        |
| 10.7 Does Changing the Metabolism of Hepatocytes through Manipulation of Methionine Metabolism Hold Promise for Improving HCC Prognosis? | 184        |
| 10.8 Conclusions                                                                                                                         | 185        |
| 10.9 Financial Support                                                                                                                   | 185        |

## PART II DYNAMICS

|                                                                                                        |            |
|--------------------------------------------------------------------------------------------------------|------------|
| <b>11 Amino Acid Transport Across Each Side of the Blood-Brain Barrier</b>                             | <b>191</b> |
| <i>R.A. Hawkins, J.R. Viña, D.R. Peterson, R. O'Kane, A. Mokashi and I.A. Simpson</i>                  |            |
| 11.1 Abstract                                                                                          | 191        |
| 11.2 Introduction                                                                                      | 192        |
| 11.3 A New Approach to Studying the BBB                                                                | 194        |
| 11.4 Facilitative Amino Acid Transporters of the BBB                                                   | 194        |
| 11.4.1 Facilitative transport of large essential neutral amino acids: system L1                        | 195        |
| 11.4.2 Facilitative transport of cationic amino acids: system y <sup>+</sup>                           | 195        |
| 11.4.3 Facilitative transport of glutamine: system n                                                   | 196        |
| 11.4.4 Facilitative transport of acidic amino acids: system x <sub>C</sub> <sup>-</sup>                | 196        |
| 11.5 Amino Acid Gradients between Brain and Plasma                                                     | 197        |
| 11.6 Na <sup>+</sup> -dependent Transport Systems of the BBB                                           | 197        |
| 11.6.1 Na <sup>+</sup> -dependent transport of large neutral amino acids: system Na <sup>+</sup> -LNAA | 199        |
| 11.6.2 Na <sup>+</sup> -dependent transport of small non-essential neutral amino acids: system A       | 199        |
| 11.6.3 Na <sup>+</sup> -dependent transport of some large and small neutral amino acids: system ASC    | 199        |
| 11.6.4 Na <sup>+</sup> -dependent transport of nitrogen-rich amino acids: system N                     | 200        |
| 11.6.5 Na <sup>+</sup> -dependent transport of acidic amino acids: the EAAT family                     | 200        |
| 11.7 Organization of the Various Transport Systems                                                     | 200        |
| 11.8 Branched-chain Amino Acids and Brain Function                                                     | 201        |
| 11.9 Glutamate in Plasma and Brain                                                                     | 201        |
| 11.9.1 Compartmentation of glutamate                                                                   | 202        |
| 11.9.2 Excitotoxicity hypothesis of neuronal death                                                     | 202        |
| 11.9.3 Glutamate in circulation                                                                        | 202        |
| 11.10 Facilitative and Active Transport Systems for Glutamate in the BBB                               | 202        |
| 11.10.1 Facilitative transport of glutamate in the luminal membrane                                    | 203        |
| 11.10.2 Active transport systems expel glutamate from the ECF                                          | 203        |
| 11.10.3 Current concept of glutamate transport across the BBB                                          | 203        |
| 11.11 Glutamine and Ammonia Balance                                                                    | 205        |
| 11.11.1 Facilitative transport of glutamine at the luminal membrane                                    | 205        |
| 11.11.2 Na <sup>+</sup> -dependent transport of glutamine at the abluminal membrane                    | 205        |
| 11.11.3 Ammonia balance                                                                                | 205        |

|                                                                                                                                      |            |
|--------------------------------------------------------------------------------------------------------------------------------------|------------|
| 11.12 The $\gamma$ -Glutamyl Cycle and the Role of Pyroglutamate<br>on Na <sup>+</sup> -dependent Carriers                           | 206        |
| 11.13 Concluding Comments                                                                                                            | 208        |
| 11.14 Acknowledgements                                                                                                               | 208        |
| <b>12 Inter-organ Fluxes of Amino Acids</b>                                                                                          | <b>215</b> |
| <i>M.C.G. van de Poll and C.H.C. Dejong</i>                                                                                          |            |
| 12.1 Abstract                                                                                                                        | 215        |
| 12.2 Introduction                                                                                                                    | 216        |
| 12.3 Glutamine and Ammonia                                                                                                           | 216        |
| 12.3.1 Metabolism                                                                                                                    | 216        |
| 12.3.2 Pathophysiology                                                                                                               | 220        |
| 12.3.2.1 Critical illness and trauma                                                                                                 | 220        |
| 12.3.2.2 Hyperammonaemia                                                                                                             | 221        |
| 12.4 Glutamine, Citrulline and Arginine                                                                                              | 222        |
| 12.4.1 Physiology                                                                                                                    | 222        |
| 12.4.1.1 Glutamine and citrulline                                                                                                    | 222        |
| 12.4.1.2 Citrulline and arginine                                                                                                     | 223        |
| 12.4.2 Metabolism after enteral administration                                                                                       | 224        |
| 12.4.2.1 Glutamine                                                                                                                   | 224        |
| 12.4.2.2 Arginine                                                                                                                    | 224        |
| 12.4.2.3 Citrulline                                                                                                                  | 225        |
| 12.5 Recommendations for Future Research                                                                                             | 225        |
| 12.6 Conclusions                                                                                                                     | 226        |
| <b>13 Cellular Adaptation to Amino Acid Availability: Mechanisms Involved<br/>in the Regulation of Gene Expression</b>               | <b>229</b> |
| <i>J. Averous, S. Lambert-Langlais, C. Chaveroux, L. Parry, V. Carraro, A.-C. Maurin,<br/>C. Jousse, A. Bruhat and P. Fafournoux</i> |            |
| 13.1 Abstract                                                                                                                        | 229        |
| 13.2 Introduction                                                                                                                    | 229        |
| 13.3 Regulation of Amino Acid Metabolism and Homeostasis<br>in the Whole Animal                                                      | 230        |
| 13.3.1 Free amino acid pool                                                                                                          | 230        |
| 13.3.2 Specific examples of the role of amino acids in the adaptation<br>to protein deficiency                                       | 231        |
| 13.3.2.1 Protein undernutrition                                                                                                      | 231        |
| 13.3.2.2 Imbalanced diet                                                                                                             | 231        |
| 13.4 Molecular Mechanisms Involved in the Regulation of Gene Expression<br>by Amino Acid Limitation                                  | 232        |
| 13.4.1 Transcriptional activation of mammalian genes by amino acid starvation                                                        | 232        |
| 13.4.1.1 Regulation of the human CHOP gene by amino acid starvation                                                                  | 233        |
| 13.4.1.2 Regulation of the asparagine synthetase gene by amino acid starvation                                                       | 233        |
| 13.4.1.3 Transcription factors binding the AARE                                                                                      | 234        |
| 13.4.1.3.1 ATF4                                                                                                                      | 234        |
| 13.4.1.3.2 ATF2                                                                                                                      | 234        |
| 13.4.1.3.3 Role of ATF4 and ATF2 in the control of the<br>AARE-dependent transcription                                               | 235        |
| 13.4.2 Signalling pathways regulated by amino acid limitation                                                                        | 235        |
| 13.4.2.1 The GCN2/ATF4 pathway (the AAR pathway)                                                                                     | 235        |
| 13.4.2.2 Signalling pathway leading to ATF2 phosphorylation                                                                          | 236        |

|                                                                                                                                 |            |
|---------------------------------------------------------------------------------------------------------------------------------|------------|
| 13.4.2.3 Other signalling pathways                                                                                              | 236        |
| 13.5 Control of Physiological Function by the GCN2/ATF4 Pathway                                                                 | 236        |
| 13.5.1 Amino acid deficiency sensing by GCN2 triggers food aversion                                                             | 236        |
| 13.5.2 Role of GCN2 in the regulation of neuronal plasticity                                                                    | 237        |
| 13.5.3 Role of GCN2 in the regulation of fatty-acid homeostasis during leucine deprivation                                      | 237        |
| 13.5.4 Role of GCN2 in the immune system                                                                                        | 238        |
| 13.6 Conclusions                                                                                                                | 238        |
| <b>PART III NUTRITION</b>                                                                                                       | <b>243</b> |
| <b>14 Endogenous Amino Acids at the Terminal Ileum of the Adult Human</b>                                                       | <b>245</b> |
| <i>P.J. Moughan</i>                                                                                                             |            |
| 14.1 Abstract                                                                                                                   | 245        |
| 14.2 Introduction                                                                                                               | 245        |
| 14.3 Endogenous Ileal Amino Acid Losses – How Should They be Determined?                                                        | 246        |
| 14.3.1 The collection of ileal digesta                                                                                          | 246        |
| 14.3.2 Quantification of the endogenous component                                                                               | 247        |
| 14.3.2.1 Protein-free diet                                                                                                      | 247        |
| 14.3.2.2 Enzyme hydrolysed protein/ultrafiltration method                                                                       | 247        |
| 14.3.2.3 Isotope dilution                                                                                                       | 248        |
| 14.4 Determined Estimates of Endogenous Ileal Nitrogen and Amino Acid Losses in Humans                                          | 248        |
| 14.5 Factors Influencing Endogenous Ileal Amino Acid Losses                                                                     | 249        |
| 14.6 Practical Relevance of Measures of Endogenous Ileal Nitrogen                                                               | 249        |
| 14.6.1 Metabolic cost                                                                                                           | 249        |
| 14.6.2 Contribution to amino acid requirement                                                                                   | 250        |
| 14.6.3 True ileal amino acid digestibility                                                                                      | 251        |
| 14.7 Conclusions                                                                                                                | 252        |
| <b>15 Metabolic Availability of Amino Acids in Food Proteins: New Methodology</b>                                               | <b>256</b> |
| <i>C.L. Levesque, R. Elango and R.O. Ball</i>                                                                                   |            |
| 15.1 Abstract                                                                                                                   | 256        |
| 15.2 Introduction                                                                                                               | 256        |
| 15.3 Methods to Estimate Protein Quality                                                                                        | 257        |
| 15.4 Metabolic Availability of Amino Acids in Food Protein Sources                                                              | 258        |
| 15.4.1 Concepts of indicator amino acid oxidation                                                                               | 258        |
| 15.4.2 Application of indicator amino acid oxidation to determine metabolic availability of amino acids in food protein sources | 260        |
| 15.4.3 Validation of the metabolic availability method                                                                          | 261        |
| 15.5 Conclusions                                                                                                                | 263        |
| <b>16 Amino Acid Requirements: Quantitative Estimates</b>                                                                       | <b>267</b> |
| <i>R.R. Pillai and A.V. Kurpad</i>                                                                                              |            |
| 16.1 Abstract                                                                                                                   | 267        |
| 16.2 Introduction                                                                                                               | 268        |
| 16.3 Nitrogen Balance                                                                                                           | 268        |
| 16.4 Isotopic Tracer Methods                                                                                                    | 271        |
| 16.4.1 Direct amino acid oxidation and balance                                                                                  | 272        |
| 16.4.2 Indicator amino acid oxidation and balance                                                                               | 276        |
| 16.4.3 Post-prandial protein utilization                                                                                        | 280        |

|           |                                                                                                  |            |
|-----------|--------------------------------------------------------------------------------------------------|------------|
| 16.5      | Factorial Prediction of Amino Acid Requirements                                                  | 281        |
| 16.6      | Estimates of the Amino Acid Requirement in Potentially Adapted States                            | 282        |
| 16.7      | Conclusions                                                                                      | 283        |
| <b>17</b> | <b>Amino Acid Supplements and Muscular Performance</b>                                           | <b>291</b> |
|           | <i>T.A. Churchward-Venne, D.W.D. West and S.M. Phillips</i>                                      |            |
| 17.1      | Abstract                                                                                         | 291        |
| 17.2      | Introduction                                                                                     | 292        |
| 17.3      | Amino Acids and Protein Turnover                                                                 | 292        |
| 17.4      | Muscle Protein Synthesis                                                                         | 293        |
| 17.5      | Enhancing Adaptations to Resistance Exercise with Amino Acid and Protein Supplements             | 293        |
| 17.5.1    | Acute studies                                                                                    | 294        |
| 17.5.2    | Chronic studies                                                                                  | 295        |
| 17.5.3    | Dose and distribution considerations to maximize MPS                                             | 296        |
| 17.6      | Enhancing Endurance Exercise Performance and Recovery with Amino Acid and Protein Supplements    | 296        |
| 17.6.1    | Amino acids and recovery from endurance exercise                                                 | 297        |
| 17.6.2    | Role of protein and amino acids in endurance exercise performance                                | 298        |
| 17.7      | Cell Signalling Responses to Amino Acids and Resistance Exercise                                 | 298        |
| 17.7.1    | Cell signalling pathways involved in translation initiation and elongation                       | 299        |
| 17.7.2    | Cell signalling response to amino acids                                                          | 299        |
| 17.7.3    | Cell signalling response to amino acids and exercise                                             | 299        |
| 17.8      | Timing Considerations                                                                            | 300        |
| 17.8.1    | Nutrient timing and acute exercise                                                               | 300        |
| 17.8.2    | Nutrient timing and chronic exercise                                                             | 300        |
| 17.9      | Amino Acid Source                                                                                | 301        |
| 17.9.1    | Acute studies                                                                                    | 301        |
| 17.9.2    | Chronic studies                                                                                  | 302        |
| 17.10     | Role of Leucine and Amino Acid Supplements in the Sarcopenia of Ageing                           | 302        |
| 17.11     | Conclusions and Future Directions                                                                | 303        |
| <b>18</b> | <b>Amino Acids in Clinical and Nutritional Support: Glutamine in Duchenne Muscular Dystrophy</b> | <b>312</b> |
|           | <i>E. Mok and R. Hankard</i>                                                                     |            |
| 18.1      | Abstract                                                                                         | 312        |
| 18.2      | Introduction                                                                                     | 312        |
| 18.3      | Duchenne Muscular Dystrophy: the Role of Muscle in Glutamine Metabolism                          | 313        |
| 18.4      | Glutamine Supplementation in Children with Duchenne Muscular Dystrophy                           | 316        |
| 18.4.1    | Acute glutamine on protein metabolism                                                            | 316        |
| 18.4.2    | Long-term glutamine on clinical outcomes                                                         | 317        |
| 18.5      | Conclusions and Future Research                                                                  | 318        |
| <b>19</b> | <b>Adverse Effects</b>                                                                           | <b>322</b> |
|           | <i>J.P.F. D'Mello</i>                                                                            |            |
| 19.1      | Abstract                                                                                         | 322        |
| 19.2      | Introduction                                                                                     | 323        |
| 19.3      | Classification                                                                                   | 323        |
| 19.4      | Amino Acid Imbalance                                                                             | 324        |
| 19.4.1    | Concept                                                                                          | 324        |

|                                                            |            |
|------------------------------------------------------------|------------|
| 19.4.2 Dietary or nutritional amino acid imbalance         | 324        |
| 19.4.2.1 Anorexia                                          | 326        |
| 19.4.2.2 Dietary preferences                               | 326        |
| 19.4.2.3 Mechanisms                                        | 326        |
| 19.4.2.4 Effects on nutrient utilization                   | 327        |
| 19.5 Clinical Amino Acid Imbalance                         | 328        |
| 19.5.1 Septic encephalopathy                               | 329        |
| 19.5.2 Liver disorders                                     | 330        |
| 19.5.3 Cancer and other conditions                         | 330        |
| 19.5.4 Appetite                                            | 330        |
| 19.6 Amino Acid Antagonisms                                | 331        |
| 19.6.1 Branched-chain amino acid antagonisms               | 331        |
| 19.6.1.1 Leucine and pellagra                              | 332        |
| 19.6.2 The lysine–arginine antagonism                      | 332        |
| 19.6.2.1 Hyperlysinaemia                                   | 332        |
| 19.6.3 Antagonisms induced by non-protein amino acids      | 333        |
| 19.6.3.1 Analogues of arginine                             | 333        |
| 19.6.3.1.1 Canavanine                                      | 333        |
| 19.6.3.1.2 Homoarginine                                    | 335        |
| 19.6.3.1.3 Indospicine                                     | 336        |
| 19.6.3.2 Analogues of sulphur-containing amino acids       | 336        |
| 19.6.3.2.1 Selenoamino acids                               | 336        |
| 19.6.3.2.2 S-Methylcysteine sulfoxide                      | 337        |
| 19.6.3.3 Mimosine                                          | 337        |
| 19.6.3.4 Neurotoxic amino acids                            | 337        |
| 19.6.3.4.1 $\beta$ -N-Oxalylamino-L-alanine                | 337        |
| 19.6.3.4.2 $\beta$ -Cyanoalanine                           | 337        |
| 19.6.3.4.3 $\alpha,\gamma$ -Diaminobutyric acid            | 338        |
| 19.6.3.4.4 $\beta$ -N-Methylamino-L-alanine                | 338        |
| 19.6.3.5 Hypoglycin A                                      | 338        |
| 19.6.3.6 Mechanisms                                        | 339        |
| 19.6.3.6.1 Arginine analogues                              | 339        |
| 19.6.3.6.2 Analogues of the sulphur-containing amino acids | 340        |
| 19.6.3.6.3 Mimosine                                        | 341        |
| 19.6.3.6.4 Neurotoxic amino acids                          | 341        |
| 19.6.3.6.5 Hypoglycin A                                    | 341        |
| 19.6.3.6.6 Underlying themes                               | 341        |
| 19.7 Amino Acid Toxicity                                   | 342        |
| 19.7.1 Glutamate                                           | 342        |
| 19.7.2 Homocysteine                                        | 342        |
| 19.7.3 Modified lysine residues                            | 342        |
| 19.7.4 Phenylalanine                                       | 343        |
| 19.8 Potential Applications                                | 343        |
| 19.8.1 Neuropsychological investigations                   | 343        |
| 19.8.2 Therapeutic aspects                                 | 343        |
| 19.9 Conclusions                                           | 345        |
| <b>20 The Umami Taste of Glutamate</b>                     | <b>353</b> |
| X. Li                                                      |            |
| 20.1 Abstract                                              | 353        |
| 20.2 Introduction                                          | 353        |

|                                               |     |
|-----------------------------------------------|-----|
| 20.3 The Taste Sensory System                 | 354 |
| 20.4 The T1R Family of Taste Receptor         | 355 |
| 20.5 Functional Expression of T1R             | 356 |
| 20.6 T1R Knockout Mice                        | 358 |
| 20.7 The Molecular Mechanism of Umami Synergy | 358 |
| 20.8 Umami Signal Transduction                | 361 |
| 20.9 Functional Neuroimaging of Umami Taste   | 362 |
| 20.10 Conclusions                             | 363 |

## **PART IV HEALTH 367**

### **21 Homocysteine Status: Factors Affecting and Health Risks 369**

*L.M. Steffen and B. Steffen*

|                                                                                                    |     |
|----------------------------------------------------------------------------------------------------|-----|
| 21.1 Abstract                                                                                      | 369 |
| 21.2 Introduction and Objectives                                                                   | 369 |
| 21.3 The Metabolism of Homocysteine                                                                | 370 |
| 21.4 Distribution of Homocysteine Concentrations<br>in the US Population                           | 370 |
| 21.5 The Determinants of Serum Total Homocysteine Concentrations                                   | 370 |
| 21.5.1 Demographic characteristics                                                                 | 370 |
| 21.5.2 Diet                                                                                        | 370 |
| 21.5.3 Smoking                                                                                     | 371 |
| 21.5.4 Medical conditions and medication use                                                       | 371 |
| 21.5.5 Genetic factors                                                                             | 372 |
| 21.6 Homocysteinaemia is a Risk Factor                                                             | 372 |
| 21.6.1 Coronary heart disease, stroke and venous thromboembolism                                   | 372 |
| 21.6.2 Cognitive function, dementia and Alzheimer's disease                                        | 373 |
| 21.7 Clinical Efficacy of Folate and Vitamins B <sub>6</sub> and B <sub>12</sub>                   | 373 |
| 21.7.1 Homocysteine, folate, vitamin B <sub>6</sub> , vitamin B <sub>12</sub> and vascular disease | 373 |
| 21.7.2 Coronary heart disease, stroke and venous thromboembolism                                   | 373 |
| 21.7.2.1 Observational studies                                                                     | 373 |
| 21.7.2.2 Randomized clinical trials                                                                | 373 |
| 21.7.3 Cognitive function, dementia and Alzheimer's disease                                        | 373 |
| 21.8 Neural Tube Defects                                                                           | 376 |
| 21.9 Methodological Issues                                                                         | 376 |
| 21.9.1 Differences among studies of homocysteine, B vitamins<br>and vascular disease               | 376 |
| 21.10 Conclusions                                                                                  | 377 |

### **22 Modified Amino Acid-Based Molecules: Accumulation and Health Implications 382**

*S. Bengmark*

|                                                                                      |     |
|--------------------------------------------------------------------------------------|-----|
| 22.1 Abstract                                                                        | 382 |
| 22.2 Introduction                                                                    | 383 |
| 22.3 Effects of Heating on Food Quality                                              | 383 |
| 22.4 AGE/ALE Accumulation in the Body                                                | 384 |
| 22.5 Modern Molecular Biology: Essential for Understanding<br>the Effects of AGE/ALE | 384 |
| 22.6 RAGE: a Master Switch and Key to Inflammation                                   | 385 |
| 22.7 Factors Underlying Enhanced Systemic Inflammation                               | 386 |
| 22.8 Dietary Choice                                                                  | 387 |
| 22.9 Dairy in Focus                                                                  | 387 |

|                                                                                                          |            |
|----------------------------------------------------------------------------------------------------------|------------|
| 22.10 AGE/ALE and Disease                                                                                | 388        |
| 22.10.1 Allergy and autoimmune diseases                                                                  | 388        |
| 22.10.2 Alzheimer's disease and other neurodegenerative diseases                                         | 388        |
| 22.10.3 Atherosclerosis and other cardiovascular disorders                                               | 389        |
| 22.10.4 Cancer                                                                                           | 390        |
| 22.10.5 Cataract and other eye disorders                                                                 | 390        |
| 22.10.6 Diabetes                                                                                         | 391        |
| 22.10.7 Endocrine disorders                                                                              | 391        |
| 22.10.8 Gastrointestinal disorders                                                                       | 392        |
| 22.10.9 Liver disorders                                                                                  | 392        |
| 22.10.10 Lung disorders                                                                                  | 392        |
| 22.10.11 Rheumatoid arthritis and other skeletomuscular disorders                                        | 392        |
| 22.10.12 Skin and oral cavity issues                                                                     | 393        |
| 22.10.13 Urogenital disorders                                                                            | 394        |
| 22.11 Foods Rich in AGE/ALE                                                                              | 394        |
| 22.12 Prevention and Treatment of AGE/ALE Accumulation                                                   | 395        |
| 22.12.1 Changing food preparation habits                                                                 | 395        |
| 22.12.2 Energy restriction                                                                               | 395        |
| 22.12.3 Antioxidants and vitamins                                                                        | 396        |
| 22.12.4 Supplementing histidine, taurine, carnitine, or carnosine                                        | 396        |
| 22.12.5 Pharmaceuticals                                                                                  | 396        |
| 22.13 Pro- and Synbiotics                                                                                | 396        |
| 22.14 Conclusions                                                                                        | 397        |
| <b>23 Phenylketonuria: Newborn Identification Through to Adulthood</b>                                   | <b>406</b> |
| <i>R. Koch and K. Moseley</i>                                                                            |            |
| 23.1 Abstract                                                                                            | 406        |
| 23.2 Introduction                                                                                        | 406        |
| 23.3 Background                                                                                          | 407        |
| 23.4 Current Problem: Maternal PKU Therapy                                                               | 407        |
| 23.5 The Role of Tetrahydrobiopterin (BH <sub>4</sub> ) Treatment for Patients with PKU                  | 408        |
| 23.6 Dietary Therapy                                                                                     | 409        |
| 23.6.1 Large neutral amino acids                                                                         | 412        |
| 23.6.2 Glycomacropeptide                                                                                 | 412        |
| 23.6.3 Tetrahydrobiopterin                                                                               | 412        |
| 23.7 Future Research                                                                                     | 413        |
| 23.8 Conclusions                                                                                         | 413        |
| <b>24 Principles of Rapid Tryptophan Depletion and its Use in Research on Neuropsychiatric Disorders</b> | <b>418</b> |
| <i>F.D. Zepf</i>                                                                                         |            |
| 24.1 Abstract                                                                                            | 418        |
| 24.2 Introduction                                                                                        | 418        |
| 24.3 Basic Principles                                                                                    | 419        |
| 24.4 RTD Protocol                                                                                        | 420        |
| 24.4.1 Before administration                                                                             | 421        |
| 24.4.2 Administration of amino acids                                                                     | 421        |
| 24.5 Effects on Mood                                                                                     | 421        |
| 24.6 Side Effects and Metabolic Complications                                                            | 422        |
| 24.7 Positron Emission Tomography Studies                                                                | 422        |
| 24.8 Conclusions                                                                                         | 423        |

|                                                                                                                      |            |
|----------------------------------------------------------------------------------------------------------------------|------------|
| <b>25 Excitatory Amino Acids in Neurological and Neurodegenerative Disorders</b>                                     | <b>427</b> |
| <i>G. Flores, J.V. Negrete-Díaz, M. Carrión, Y. Andrade-Talavera, S.A. Bello, T.S. Sihra and A. Rodríguez-Moreno</i> |            |
| 25.1 Abstract                                                                                                        | 427        |
| 25.2 Introduction                                                                                                    | 428        |
| 25.3 Alzheimer's Disease and Glutamate Receptors                                                                     | 428        |
| 25.4 Parkinson's Disease and Glutamate Receptors                                                                     | 429        |
| 25.5 Huntington's Disease                                                                                            | 430        |
| 25.5.1 Animal models                                                                                                 | 432        |
| 25.6 Schizophrenia and Glutamate Receptors                                                                           | 434        |
| 25.7 Depression and Glutamate Receptors                                                                              | 435        |
| 25.8 Epilepsy and Glutamate Neurotransmission                                                                        | 436        |
| 25.8.1 Excitatory amino acids in epilepsy                                                                            | 436        |
| 25.8.2 Kainate receptors in epilepsy                                                                                 | 437        |
| 25.9 Amyotrophic Lateral Sclerosis and Excitatory Amino Acids                                                        | 440        |
| 25.9.1 Glutamate receptors and excitotoxicity in ALS                                                                 | 441        |
| 25.9.2 Glutamate metabolism and transport in ALS                                                                     | 442        |
| 25.10 Stroke                                                                                                         | 442        |
| 25.10.1 Background                                                                                                   | 442        |
| 25.10.2 Glutamate and glutamate receptors in cerebral ischaemia                                                      | 443        |
| 25.11 Conclusions                                                                                                    | 445        |
| <b>26 Efficacy of L-DOPA Therapy in Parkinson's Disease</b>                                                          | <b>454</b> |
| <i>G. Sahin and D. Kirik</i>                                                                                         |            |
| 26.1 Abstract                                                                                                        | 454        |
| 26.2 Introduction                                                                                                    | 454        |
| 26.3 L-DOPA                                                                                                          | 455        |
| 26.4 Dopamine Biosynthesis in Physiological Conditions                                                               | 456        |
| 26.5 Basic Principles of L-DOPA Pharmacotherapy<br>in Parkinson's Disease                                            | 456        |
| 26.6 Clinical Pharmacokinetics and Pharmacodynamics of L-DOPA Therapy                                                | 458        |
| 26.7 L-DOPA-induced Dyskinesias                                                                                      | 458        |
| 26.8 Gene Therapy-mediated Continuous DOPA Delivery<br>in the Parkinsonian Brain                                     | 459        |
| 26.9 Summary and Concluding Remarks                                                                                  | 460        |
| <b>27 Amino Acid Profiles for Diagnostic Applications</b>                                                            | <b>464</b> |
| <i>T. Kimura, M. Takahashi, A. Imaizumi, Y. Noguchi and T. Ando</i>                                                  |            |
| 27.1 Abstract                                                                                                        | 464        |
| 27.2 Introduction                                                                                                    | 464        |
| 27.3 Correlation-based Analysis of Amino Acids                                                                       | 465        |
| 27.4 Development of Amino Acid Diagnostics                                                                           | 465        |
| 27.4.1 Background                                                                                                    | 465        |
| 27.4.2 Initial studies                                                                                               | 466        |
| 27.4.3 Measurement of amino acids                                                                                    | 468        |
| 27.5 Clinical Applications                                                                                           | 468        |
| 27.5.1 Factors influencing stability of data                                                                         | 468        |
| 27.5.2 Application of AminoIndex to liver fibrosis                                                                   | 468        |
| 27.5.3 Application of AminoIndex to metabolic syndrome                                                               | 470        |
| 27.5.4 Application of AminoIndex to colorectal and breast cancer                                                     | 472        |
| 27.6 Future Perspectives                                                                                             | 472        |

|                                                                        |            |
|------------------------------------------------------------------------|------------|
| <b>PART V CONCLUSIONS</b>                                              | <b>477</b> |
| <b>28 Emergence of a New Momentum</b>                                  | <b>479</b> |
| <i>J.P.F. D'Mello</i>                                                  |            |
| 28.1 Abstract                                                          | 479        |
| 28.2 Rationale                                                         | 480        |
| 28.3 Objectives and Approach                                           | 480        |
| 28.4 Key Enzymes and Pathways                                          | 481        |
| 28.4.1 Glutamate dehydrogenase                                         | 482        |
| 28.4.2 Aminotransferases (transaminases)                               | 483        |
| 28.4.3 Glutamate decarboxylase                                         | 484        |
| 28.4.4 Glutamine synthetase                                            | 484        |
| 28.4.5 Glutaminase                                                     | 484        |
| 28.4.6 Ornithine decarboxylase                                         | 484        |
| 28.4.7 Urea-cycle enzymes                                              | 485        |
| 28.4.7.1 Arginase                                                      | 485        |
| 28.4.8 Nitric oxide synthase                                           | 485        |
| 28.4.9 Histidine decarboxylase                                         | 485        |
| 28.4.10 Serine racemase                                                | 485        |
| 28.4.11 Hydroxylases                                                   | 486        |
| 28.4.12 Enzymes of methionine metabolism                               | 486        |
| 28.5 Neurotransmitters                                                 | 487        |
| 28.5.1 Glutamate                                                       | 487        |
| 28.5.2 Aspartate                                                       | 488        |
| 28.5.3 Proline                                                         | 488        |
| 28.5.4 $\gamma$ -Aminobutyrate and glycine                             | 488        |
| 28.5.5 D-Serine                                                        | 489        |
| 28.5.6 $\beta$ -Alanine and taurine                                    | 489        |
| 28.5.7 Gases                                                           | 489        |
| 28.6 Molecular Interactions                                            | 490        |
| 28.6.1 Transport                                                       | 490        |
| 28.6.2 Leucine signalling                                              | 491        |
| 28.6.3 Hormonal modulation                                             | 491        |
| 28.6.4 Umami flavour                                                   | 492        |
| 28.6.5 Post-translational adducts                                      | 492        |
| 28.6.5.1 Advanced glycation end-products                               | 492        |
| 28.6.5.2 Proline-rich proteins                                         | 492        |
| 28.7 Clinical Support                                                  | 493        |
| 28.7.1 Biochemical considerations                                      | 493        |
| 28.7.2 Supplements                                                     | 493        |
| 28.8 Food Toxicology                                                   | 496        |
| 28.8.1 Nitrate and nitrite                                             | 496        |
| 28.8.2 Plant neurotoxins                                               | 496        |
| 28.8.3 Monosodium glutamate                                            | 496        |
| 28.8.4 Maillard products                                               | 496        |
| 28.8.5 Lysinoalanine                                                   | 497        |
| 28.9 Disorders                                                         | 497        |
| 28.9.1 Clinical amino acid imbalance                                   | 497        |
| 28.9.2 Obesity                                                         | 497        |
| 28.9.3 Neuropathologies                                                | 498        |
| 28.9.3.1 Conditions associated with glutamate excitotoxicity           | 501        |
| 28.9.3.2 Psychological and cognitive impairments: emerging methodology | 502        |

|                                                      |     |
|------------------------------------------------------|-----|
| 28.9.4 Cardiovascular disease                        | 503 |
| 28.9.5 Diabetes                                      | 503 |
| 28.9.6 Cancer                                        | 504 |
| 28.9.7 Genetic defects                               | 505 |
| 28.9.8 Risk factors                                  | 505 |
| 28.9.9 Therapeutics                                  | 506 |
| 28.9.10 Dietary modulation                           | 506 |
| 28.9.11 Non-protein amino acids in cancer prevention | 507 |
| 28.9.12 Molecular targets                            | 507 |
| 28.9.12.1 Enzymes                                    | 507 |
| 28.9.12.2 Aminoacidergic and monoaminergic receptors | 508 |
| 28.9.12.3 Transporters                               | 509 |
| 28.10 Innovation                                     | 509 |
| 28.10.1 Modelling                                    | 509 |
| 28.11 Summary                                        | 510 |
| 28.11.1 Underlying theme                             | 510 |
| 28.11.2 Metabolism                                   | 510 |
| 28.11.3 Nutrition                                    | 510 |
| 28.11.4 Food safety                                  | 511 |
| 28.11.5 Health and disease                           | 511 |
| 28.12 Outlook                                        | 512 |